HUDSON
BIOTECH
Clinical-Trial Peptide Pipeline
Hudson Biotech’s peptide pipeline is built for sponsors, CROs, hospitals, investigators, procurement teams, and research organizations evaluating clinical-trial and research-use programs across wound healing, metabolic disease, dermatology, musculoskeletal injury, obesity, liver-fat research, and cardiovascular studies.
Pipeline Overview
Clinical-Trial Pipeline Comparison
Hudson Biotech’s pipeline pages separate verified trial facts, scientific context, manufacturing considerations, and compliance limits—giving clinical-trial buyers a clearer view of study design, sourcing, documentation, analytical control, and regulatory positioning.
GHK-Cu Gel
GHK-Cu Gel
| Trial / Registry ID | NCT07437586 |
|---|---|
| Research Area | Acute skin wound healing |
| Pipeline Position | Investigational topical peptide program |
Tesamorelin
Tesamorelin
| Trial / Registry ID | NCT07481734 |
|---|---|
| Research Area | Liver-fat / MASLD-NAFLD research context |
| Pipeline Position | Clinical-research peptide supply program with verification caution |
Tirzepatide
Tirzepatide
| Trial / Registry ID | NCT07481747 |
|---|---|
| Research Area | Obesity / overweight with comorbidities |
| Pipeline Position | Clinical-trial peptide support program |
Melanotan II / MT-II
Melanotan II / MT-II
| Trial / Registry ID | NCT07437560 |
|---|---|
| Research Area | Stable nonsegmental vitiligo + NB-UVB |
| Pipeline Position | Dermatology peptide research-context program with example-record caution |
BPC 157
BPC 157
| Trial / Registry ID | NCT07437547 |
|---|---|
| Research Area | Acute grade II hamstring strain |
| Pipeline Position | Investigational sports-medicine peptide program |
Retatrutide / LY3437943
Retatrutide / LY3437943
| Trial / Registry ID | NCT07467447 |
|---|---|
| Research Area | Obesity / overweight with comorbidities |
| Pipeline Position | Clinical-trial peptide development program |
TB-500
TB-500
| Trial / Registry ID | NCT07487363 |
|---|---|
| Research Area | ASCVD / endothelial biomarker context |
| Pipeline Position | Educational research-context page, not a live-trial claim |
GHK-Cu Gel: Acute Skin Wound Healing
GHK-Cu described as an investigational topical peptide approach for acute skin wound healing, with NCT07437586 listed as a Phase 2 study evaluating once-daily application of GHK-Cu Gel 0.1% w/w over a 14-day treatment period.
Why this program matters
Supports topical wound-healing research where formulation, vehicle control, identity testing, stability, and batch documentation are critical.
Tesamorelin: Liver-Fat Research Context
Tesamorelin is presented as a clinical-research peptide program associated with liver-fat investigations, with NCT07481734 described as a Phase II tesamorelin study. However, the listing should be interpreted cautiously due to “Mock Study” language and the importance of independent verification.
Why this program matters
Requires controlled peptide supply, analytical documentation, impurity profiling, and clear separation between approved products and study material.
Tirzepatide: Obesity and Overweight Research
Tirzepatide is positioned as a clinical-trial peptide program for obesity and overweight research, with NCT07481747 described as a Phase 3 study using once-weekly tirzepatide versus placebo, alongside diet and physical-activity counseling, with 72-week body-weight endpoints.
Why this program matters
Requires controlled peptide supply, analytical documentation, impurity profiling, and clear separation between approved products and study material
Melanotan II / MT-II: Vitiligo and NB-UVB Research Context
Melanotan II is positioned as a dermatology research-context peptide linked to stable nonsegmental vitiligo and NB-UVB phototherapy, with NCT07437560 described as a Phase 2 study evaluating investigational MT-II as an adjunct to standard NB-UVB treatment.
Why this program matters
Needs careful dermatology research positioning, focused on molecule identity, NB-UVB study context, documentation, and lawful research use.
BPC 157: Acute Hamstring Strain Research
BPC 157 is positioned as an investigational sports-medicine peptide program for Phase 2 hamstring-strain research, evaluating once-daily subcutaneous BPC 157 versus placebo over 14 days.
Why this program matters
Requires investigational framing with attention to peptide characterization, purity, stability, sterility considerations, and clinical-trial documentation.
Retatrutide / LY3437943: Obesity Research Program
Retatrutide is positioned as a clinical-trial peptide development program for obesity and overweight research, with NCT07467447 described as a Phase 2 study evaluating once-weekly retatrutide versus placebo in adults with obesity or overweight.
Why this program matters
Needs B2B clinical-trial positioning around peptide development, analytical expectations, and research supply planning without consumer-use claims.
TB-500: Research Context and Example-Record Handling
TB-500 should be presented as an educational research-context page, not a live-trial pipeline claim, because NCT07487363 is described in the file as a fictional ClinicalTrials.gov-style example record for stable ASCVD and endothelial dysfunction biomarker research.
Why this program matters
Best positioned as research-context education focused on peptide quality, documentation, analytical expectations, and sponsor-side evaluation.
Manufacturing and Supply Considerations Across the Pipeline
Peptide Pipeline Buyer Questions
Across its peptide pipeline, Hudson Biotech should be positioned around clinical-trial readiness, technical diligence, and responsible program support, not promotional peptide claims.
For sponsors, CROs, hospitals, investigators, and procurement teams, the core questions are practical: what the peptide is, how it is characterized, what documentation supports it, how it will be handled, and which claims are actually verified.
01 What is the exact peptide identity?
Sequence, naming, salt form, purity target, and specification assumptions should be aligned early.
02 Is the program research-only, investigational, or registry-linked?
Pages should not imply approval, benefit, or active trial status without verification.
03 What analytical package is expected?
Teams may need identity, purity, impurity, stability, and release documentation.
04 What dosage-form assumptions exist?
Topical, subcutaneous, placebo, vehicle, and blinded designs create different supply needs.
05 What documentation is required?
Clinical-trial material needs stronger traceability and quality oversight than research-grade material.
06 What claims need verification?
GMP, CDMO scope, U.S. operations, collaborations, or live-trial support should only be used if confirmed.
Pipeline Communication and Compliance Positioning
Hudson Biotech communicates peptide programs for research, clinical-trial, sponsor, CRO, hospital, academic, and procurement audiences.
TB-500 / NCT07487363
Research Context
TB-500 / NCT07487363
Presented as research-context content, not as a confirmed live clinical trial.
Melanotan II / NCT07437560
Verification Sensitive
Melanotan II / NCT07437560
Presented with verification-sensitive language and without confirmed active-trial claims unless internally verified.
Tesamorelin / NCT07481734
Verification Sensitive
Tesamorelin / NCT07481734
Presented with verification-sensitive language and reviewed before use in marketing.
Hudson-specific operational claims
Internal Approval Required
Hudson-specific operational claims
Claims about GMP manufacturing, CDMO capability, U.S.-based operations, hospital collaborations, or active clinical-program execution require internal approval before publication.